Ipca Laboratories reported 12% domestic revenue growth in Q1FY25, with higher EBITDA margin. The company reduced FY25 revenue growth guidance to ~9% and raised EBITDA margin guidance to 18.5–19.0%.
What is covered in the Full Insight:
Introduction
Financial Performance
Challenges and Setbacks
Strategic Initiatives and Innovations
Share Performance and Valuation
Boomeranged on Sun, 3 Nov 2024 22:29
Ipca will announce Q2FY25 result on November 14. Thus far, Indian pharma companies have reported strong domestic revenue. We are expecting similar performance from Ipca. Accumulate before the result announcement.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.